Real-world evidence of suboptimal blood pressure control in patients with type 2 diabetes

Aims: In order to eventually improve blood pressure (BP) management, the aim of this study was to identify subgroups of type 2 diabetes mellitus (T2DM) patients with distinct trajectories of SBP levels. Identifying subgroups with distinct SBP trajectories helps to better understand the course of SBP levels in T2DM patients and its associated consequences. Subgroup characteristics were determined and the prevalence of complications and mortality rates over time in the different subgroups was investigated. Methods: Five thousand, seven hundred and eleven T2DM patients with at least two SBP follow-up measurements were selected from a prospective T2DM cohort of 9849 T2DM patients. The mean follow-up period was 5.7 years (range 2–9 years). Latent Class Growth Modeling, as currently the most flexible cluster analysis available, was performed to identify subgroups of patients with distinct SBP trajectories. Subgroup characteristics were determined by multinomial logistic regression analyses. Results: Four subgroups with distinct SBP trajectories were identified. The largest subgroup (85.6%) showed adequate SBP control (at or around 140 mmHg) over time. The second subgroup (5.6%) were hypertensive in the first years, responded slowly to BP management and eventually reached SBP control. The third subgroup (3.4%) showed deteriorating hypertension during the first 4 years, then showed insufficient response to BP management. The fourth subgroup (5.4%) showed deteriorating hypertension over time. Patients within subgroups 2–4 were significantly older, comprised more women, used more antihypertensive medication and had a higher prevalence of retinopathy, microalbuminuria and cardiovascular disease (CVD) mortality. Conclusion: More than 85% reached and maintained adequate SBP control. Subgroups with a more unfavourable course of SBP control also showed higher rates of microvascular complications and CVD mortality over time. This study identified important subgroups to target in order to improve BP management in T2DM patients.

[1]  W. Elliott.  Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document , 2010 .

[2]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[3]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[4]  Stephen J. Aldington,et al.  Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM Complications Study , 1995, Diabetologia.

[5]  V. Basevi.  Standards of Medical Care in Diabetes—2010 , 2010, Diabetes Care.

[6]  R. Holle,et al.  Blood pressure and lipid management fall far short in persons with type 2 diabetes: results from the DIAB-CORE Consortium including six German population-based studies , 2012, Cardiovascular Diabetology.

[7]  Y. Jang,et al.  Standards of Medical Care in Diabetes-2010 by the American Diabetes Association: Prevention and Management of Cardiovascular Disease , 2010 .

[8]  M. Woodward,et al.  Effects of Visit-to-Visit Variability in Systolic Blood Pressure on Macrovascular and Microvascular Complications in Patients With Type 2 Diabetes Mellitus: The ADVANCE Trial , 2013, Circulation.

[9]  José Agustín Arguedas,et al.  Blood pressure targets for hypertension in people with diabetes mellitus. , 2013, The Cochrane database of systematic reviews.

[10]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[11]  V. Basevi.  Standards of Medical Care in Diabetes—2013 , 2012, Diabetes Care.

[12]  G. Landman,et al.  Lower blood pressure associated with higher mortality in elderly diabetic patients (ZODIAC-12). , 2010, Age and ageing.

[13]  J. Tuomilehto,et al.  Blood pressure treatment target in patients with diabetes mellitus—current evidence , 2012, Annals of medicine.

[14]  K. Khunti,et al.  Association of systolic and diastolic blood pressure and all cause mortality in people with newly diagnosed type 2 diabetes: retrospective cohort study , 2012, BMJ : British Medical Journal.

[15]  A. Zanchetti,et al.  Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? , 2003, Journal of hypertension.

[16]  Jennifer Taylor,et al.  2013 ESH/ESC guidelines for the management of arterial hypertension. , 2013, European heart journal.

[17]  Bengt Muthén,et al.  The potential of growth mixture modelling , 2006 .

[18]  J. Beckman,et al.  Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I , 2013, European heart journal.

[19]  L. Welschen,et al.  Progression and Regression: Distinct Developmental Patterns of Diabetic Retinopathy in Patients With Type 2 Diabetes Treated in the Diabetes Care System West-Friesland, the Netherlands , 2011, Diabetes Care.

[20]  S. Saydah,et al.  Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. , 2004, JAMA.

[21]  P. Nilsson,et al.  Hypertension in diabetes: trends in clinical control in repeated large-scale national surveys from Sweden , 2003, Journal of Human Hypertension.

[22]  Daniel S Nagin,et al.  Group-based trajectory modeling in clinical research. , 2010, Annual review of clinical psychology.

[23]  Ettore Ambrosioni,et al.  ESH/ESC guidelines for the management of arterial hypertension: how to implement in daily clinical practice , 2004 .

[24]  J. Beckman,et al.  Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. , 2013, European heart journal.

[25]  John S Yudkin,et al.  Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study , 2000, BMJ : British Medical Journal.

[26]  N. Wong,et al.  Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: Comparison by prevalent cardiovascular disease status , 2013, Diabetes & vascular disease research.

[27]  G. Mancia,et al.  Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study , 2004, Hypertension.

[28]  W. Cushman,et al.  Diabetes and hypertension: the bad companions , 2012, The Lancet.

[29]  A. Kitabchi,et al.  Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. , 2011, Metabolism: clinical and experimental.

[30]  M. Rogers,et al.  Blood Pressure Trajectories Prior to Death in Patients With Diabetes , 2011, Diabetes Care.

[31]  David M. Blei,et al.  Build, Compute, Critique, Repeat: Data Analysis with Latent Variable Models , 2014 .

[32]  G. Nijpels,et al.  Distinct HbA1c trajectories in a type 2 diabetes cohort , 2015, Acta Diabetologica.

[33]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[34]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[35]  J. Rouleau,et al.  Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. , 2005, Journal of the American Society of Nephrology : JASN.

[36]  Jos Twisk,et al.  Classifying developmental trajectories over time should be done with great caution: a comparison between methods. , 2012, Journal of clinical epidemiology.